Solid has a diversified pipeline across neuromuscular and cardiac diseases with indications we believe are characterized by high unmet need, clear mechanistic rationale and significant market opportunities
Data from Solid’s IGNITE DMD Phase I/II clinical trial evaluating the first-generation candidate SGT-001, which used the AAV9 capsid, showed that expression of the nNOS microdystrophin transgene may have the potential to slow or stop the progression of Duchenne. In studies of SGT-003 performed in the mdx mouse model of Duchenne and in vitro in human Duchenne cell lines, multiple fold increases in microdystrophin expression have been observed in comparison to AAV9, suggesting that therapeutic dose levels using AAV-SLB101 can be lower than first generation candidates.
AVB-202-TT is a novel gene transfer product candidate being developed for the treatment of Friedrich’s ataxia. Friedrich’s ataxia is a rare inherited genetic disease caused by loss of frataxin with both neurological and cardiac manifestations affecting muscle control and coordination, with possible loss of vision and hearing and slurred speech. AVB-202-TT, like other potential gene replacement treatments for Friedrich’s ataxia, is intended to replace the frataxin gene across relevant tissues, with the goal of preventing progression or reversing the course of the disease. AVB-202-TT is in preclinical development and utilizes a dual route of administration (via both intrathecal and intravenous routes) to more rigorously target disease pathology. Preclinical data from three animal models, including mouse and nonhuman primate, supported preclinical proof of concept. Early findings in preclinical studies demonstrated improved survival and cardiac function, as well as mitochondrial function in mice.
AVB-401 is a novel gene transfer product candidate being developed for the treatment of BAG3 mediated dilated cardiomyopathy (BAG3). BAG3 is a rare cardiac disease and is characterized by mutations in the BAG3 gene. Sufficient levels of functional BAG3 are required for healthy cardiac function.
Solid is currently researching two undisclosed cardiac programs, for undisclosed cardiac indications.
As we move forward, expect to see a diversified pipeline, including emerging technologies that will be evaluated for their potential to target underlying diseases and bring groundbreaking genetic therapies to more patients